




# **Kyrgyzstan Pharmaceutical Guide**

**2009 - 2010**





UBI Consulting is a group of Uzbek professionals providing services to customers of the public and private spectrum. UBI Consulting was established in response to the increasing changes in development in Uzbekistan and other countries of Central Asia.

The company specializes in the implementation of strategic and feasibility studies, and evaluation activities and project experience that each UBI consultant brings to assignments.

PHARM GROUP is targeted onto decision-making of the first-priority objectives of pharmaceutical companies: increasing the sales of drugs.

**PHARM GROUP** assists to foreign and domestic companies in the issues of government legalization of their products in Uzbekistan.

## Disclaimer

The contents of this Handbook are derived from a variety of sources, have been researched with the utmost care and are believed to be accurate as of the beginning of December 2009. The purpose of the Handbook is to provide brief guidance to potential investors. It must not be used in place of professional advice. UBI Consulting cannot be held liable for the accuracy or implications of use of the information contained within.

© 2009-2010. All right reserved by UBI Consulting LLC

## **Preface**

This Pharmaceuticals Investment Handbook has been prepared for foreign investors considering entry into the Kyrgyz pharmaceuticals market and is designed to provide enough information to make a decision on whether investment is a potential option for you. It is intended to highlight industry potential and recent performance, backed up by quantitative and qualitative data. The handbook also suggests investment competitive advantages & opportunities and provides details of investment incentives.

Given the country's prominent history in the fine chemicals industry, the success of existing pharmaceutical manufacturers and the high skill levels of the workforce, Kyrgyzstan is worth your considering for investment; particularly in the areas of equity investment and contract manufacturing for local distribution and export.

Kyrgyz domestic market may be small but it neighbors the large and fast growing market of the CIS. Opportunities also exist for manufacturing low-volume specialized drugs that larger producers find uneconomical to produce.

Whilst it is appreciated that investors will need to carefully consider a wide variety of factors, this guide should give the reader enough background information to assess investment potential, and enable them to move forward quickly with further research. Contact details of useful organizations are provided to assist with gathering further industry insights.

A general analysis of the economic environment and investment incentives is followed by a detailed review of pharmaceutical industry performance, the regulatory environment, recent investments and investment opportunities. The third part of the handbook focuses on general information on the business environment.

## Table of Content

1. Country Information.....	6
2. Geography .....	9
3. Population and Language .....	10
4. Currency and Payments.....	12
5. Government.....	13
5.1. Executive Branch .....	13
5.2. Legislative Branch.....	13
5.3. Judicial Branch.....	13
5.4. International Organizations .....	14
6. Entry Visas & Residency .....	15
6.1. Registration in passport department.....	16
6.2. OVIR registration.....	16
7. Business Hours.....	17
8. Economic Performance .....	18
9. Investment Climate .....	19
9.1. Conversion and Transfer Policies .....	19
9.2. Guarantees for Investors.....	19
9.3. Performance Requirements and Incentives .....	20
9.4. Efficient Capital Markets and Portfolio Investment .....	21
9.5. Problems for Investment .....	22
9.6. Bilateral Investment Agreements .....	23
10. Health Care System.....	24
11. Pharmaceutical Industry at a Glance.....	27
12. Legal Framework and Regulations .....	29
12.1. The Law of Kyrgyz Republic “On Investments” .....	29
12.2. Pharmaceutical Policy, Legislation and Regulation.....	30
13. Foreign Direct Investment (FDI) in Pharmaceutical Market .....	33
13.1. Foreign Direct Investment Statistics .....	33
13.2. FDI Notification and Registration.....	33
13.3. FDI in Pharmaceutical Market .....	35
14. Licensing .....	36
15. Drug Registration .....	38
16. Main Regulatory Institutions.....	40
16.1. Department of Drug Supply and Medical Techniques.....	40
16.2. Republican Center for Development of Healthcare and Information Technologies... 40	
17. Quality Control and Assurance .....	42
18. Transportation System.....	43
18.1. Railways, highways, pipelines and waterways .....	43
18.1.1. Highways.....	43
18.1.3. Pipelines .....	43
18.1.3. Waterways .....	44
18.2. Airways and air terminals .....	44
18.3. International Travels .....	44
18.4. Internal Travels .....	45
19. Labor Relations .....	46
19.1. Work Books.....	46

19.2.	Probationary Period.....	46
19.3.	Working Week .....	46
19.4.	Holidays .....	47
19.5.	Sick Leave .....	47
19.6.	Maternity Leave .....	47
19.7.	Cost of Employment.....	47
19.8.	Foreign Workers in Kyrgyzstan .....	47
20.	Forms of Business Organization .....	48
21.	Customs and Taxation System .....	51
22.	Intellectual Property Rights and their Protection .....	53
23.	Insurance Market.....	54
24.	Zoning, Land Use and Building Permits .....	55
25.3.	Privatization .....	56
25.	Business Costs.....	56
26.	Safety issues .....	58
27.	Annexes .....	59